Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2025-09-29 Proxy Solicitation & In…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BioSenic SA_Convening notice_2025_FR_Final.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an official invitation to an Annual General Meeting (AGM) and an Extraordinary General Meeting (EGM). It contains the agenda, proposed resolutions, and details regarding shareholder voting, board appointments, and remuneration policies. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) because it provides shareholders with the necessary information to vote on corporate matters at a meeting.
2025-09-29 French
Rapport special du commissaire aux comptes.pdf
Audit Report / Information Classification · 95% confidence The document is a formal report by the statutory auditor (commissaire) regarding a transaction between Biosenic SA and a related party (4Moving Biotech SAS), specifically prepared in accordance with Article 7:97 of the Belgian Code of Companies and Associations (CSA). This article mandates a specific governance procedure for transactions between a listed company and related parties, requiring an independent committee opinion, a board minute, and an auditor's assessment of the financial data. Since this document contains the auditor's report, the independent committee's opinion, and the legal framework for these related-party transactions, it falls under the category of governance and regulatory compliance reporting. Q3 2025
2025-09-23 French
Rapport du comite d'independant.pdf
Board/Management Information Classification · 95% confidence The document is an 'Avis du Comité des Administrateurs Indépendants' (Opinion of the Independent Directors Committee) issued by BioSenic. It specifically addresses compliance with Article 7:97 of the Belgian Code of Companies and Associations regarding transactions with related parties. It details the legal framework, the nature of the transaction (a co-development agreement with 4Moving), and the committee's assessment of the conflict of interest. This type of document is a formal regulatory disclosure required for corporate governance and transparency regarding related-party transactions, fitting best under the 'Regulatory Filings' category as it is a specific legal disclosure document.
2025-09-23 French
BIOSENIC_CI_4moving_20250923_EN.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by BioSenic regarding the application of Article 7:97 of the Belgian Code on Companies and Associations (BCCA) concerning a related-party transaction with 4Moving Biotech. It details the conflict of interest procedure, the committee of independent directors' opinion, and the board's approval of the transaction. While it discusses a partnership, it is a regulatory disclosure announcement rather than a formal M&A contract or a standalone audit report. Given it is a regulatory announcement regarding corporate governance and internal procedures, it fits best under the 'Regulatory Filings' (RNS) category as a catch-all for such corporate disclosures.
2025-09-23 English
BIOSENIC_CI_4moving_20250923_FR.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from BioSenic regarding the application of Article 7:97 of the Belgian Code of Companies and Associations (CSA) concerning a conflict of interest procedure for a partnership with 4Moving Biotech. It details the board's decision-making process, the opinion of independent directors, and the auditor's review of the transaction. While it discusses a partnership, it is primarily a regulatory disclosure regarding corporate governance and conflict of interest procedures rather than a standalone M&A announcement or a financial report. Given the nature of the disclosure (regulatory compliance announcement), 'RNS' (Regulatory Filings) is the most appropriate classification.
2025-09-23 French
BIOS_PR_EN_2025 08_29.pdf
Report Publication Announcement Classification · 100% confidence The document is a short press release (under 5,000 characters) that announces a delay in the publication of the company's annual report and financial results. It does not contain the actual financial report, but rather informs stakeholders about the postponement of the reporting timeline. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-08-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.